Assertio Holdings, Inc. (ASRT)
Jun 16, 2026 - ASRT was delisted (reason: merged with Zydus Lifesciences)
23.50
+0.02 (0.09%)
Inactive · Last trade price on Jun 15, 2026

Assertio Holdings Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
102.16118.71124.96152.07156.23111.01
Revenue Growth
-14.16%-5.00%-17.83%-2.67%40.73%4.46%
Gross Profit
71.8583.3385.73125.05137.4995.18
Operating Income
-26.78-21.54-24.48-243.5439.419.42
Net Income
-30.78-30.38-21.58-331.94109.63-1.28
Earnings Per Share
-5.69-4.74-3.40-70.0530.45-0.45
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
71.5763.41100.0573.4464.9436.81
Total Debt
39.2539.1238.8138.5166.8773.49
Net Cash (Debt)
32.3224.2861.2434.93-1.93-36.68
Net Cash Growth
-33.22%-60.35%75.34%---
Net Cash Per Share
4.913.799.647.38-0.53-12.75

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-7.08-28.1826.4149.678.65.52
Capital Expenditures
----0.63-0.27-0.05
Free Cash Flow
-7.08-28.1826.4148.9878.325.47
Free Cash Flow Growth
---46.08%-37.47%1331.88%-

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
70.33%70.19%68.61%82.23%88.00%85.74%
Operating Margin
-26.21%-18.14%-19.59%-160.15%25.22%8.49%
Pretax Margin
-34.71%-25.22%-17.23%-167.06%19.95%-0.50%
Profit Margin
-30.13%-25.59%-17.27%-218.28%70.17%-1.15%
FCF Margin
-6.93%-23.74%21.13%32.21%50.13%4.93%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----2.12-
Forward PE
19.26--53.508.2611.47
P/FCF Ratio
--3.152.072.6517.79
PS Ratio
1.490.490.670.671.330.88